Lung cancer treatment study in China
Part of Cancer, Lungs & breathing clinical trials.
This study looks back at the medical records of people in China diagnosed with early-stage lung cancer (Stage I–III) to learn more about the disease and how it is treated. It does not involve any new treatments or tests—just reviewing information that was already collected during your care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with Stage I, II, or III non-small cell lung cancer (NSCLC).
- You were 18 or older at the time of your first diagnosis.
- Your diagnosis happened between May and December of one of these years: 2025, 2026, or 2027.
- Lung cancer is your main cancer (not a cancer that started elsewhere first).
- You do not have another cancer currently or recently.
- You were not in a treatment trial when first diagnosed.
- You were not pregnant at the time of diagnosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well patients with early-stage lung cancer (that has been surgically removed) do when treated with a targeted drug called EGFR-TKI to prevent cancer from coming back. Researchers will track actual patient outcomes in China from 2023 to 2026.
This trial uses special markers in the blood to find lung cancer early and track if it comes back after treatment. It is for people with non-small cell lung cancer who are able to have surgery.
This study collects and analyzes lung cancer tissue samples to understand genetic differences that may help guide future treatment. You'll provide a tissue sample (either from a biopsy or prior surgery), and researchers will study it—no treatment is given in this study.
This study is looking back at the medical records of people with early-stage non-small cell lung cancer who had surgery or radiation therapy between 2018 and 2019. The goal is to understand how patients were diagnosed and treated, which may help improve care for others in the future.
This trial collects tissue samples from your lung tumor and any tumors that have spread to other parts of your body. They will study the genetic makeup of these samples to better understand lung cancer and improve future treatments.
This trial does not test a new drug. It looks at existing medical records to compare how well different treatments work for people with advanced non-small cell lung cancer. You may be eligible if your cancer is advanced and you are not in another clinical trial.
Hear when a new Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.